Assessing the risks and benefits of step-down asthma care

a case-based approach

John B. Hagan, Matthew A Rank

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Guidelines have called for pharmacologic stepped care to improve asthma treatment. Therapeutic options which have been approved provide physicians and their patients alternatives for stepping up asthma treatment to achieve control. However, few studies have been performed to identify and characterize procedures for optimal stepping-down treatment in patients with asthma. The resulting uncertainty as well as a lack of prioritization for asthma reassessment once control has been maintained has led to a lack of well-defined procedures for stepping down asthma treatment. However, recent studies provide guidance regarding the risks of stepping down asthma medications. This review uses case-based examples to demonstrate how health care providers may engage patients in discussions regarding guideline recommendations to promote individualized asthma care.

Original languageEnglish (US)
Pages (from-to)503
Number of pages1
JournalCurrent Allergy and Asthma Reports
Volume15
Issue number8
DOIs
StatePublished - Apr 1 2015

Fingerprint

Asthma
Guidelines
Therapeutics
Health Personnel
Uncertainty
Physicians

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Assessing the risks and benefits of step-down asthma care : a case-based approach. / Hagan, John B.; Rank, Matthew A.

In: Current Allergy and Asthma Reports, Vol. 15, No. 8, 01.04.2015, p. 503.

Research output: Contribution to journalArticle

@article{690ef937394947a09bc2b7aabeebc28c,
title = "Assessing the risks and benefits of step-down asthma care: a case-based approach",
abstract = "Guidelines have called for pharmacologic stepped care to improve asthma treatment. Therapeutic options which have been approved provide physicians and their patients alternatives for stepping up asthma treatment to achieve control. However, few studies have been performed to identify and characterize procedures for optimal stepping-down treatment in patients with asthma. The resulting uncertainty as well as a lack of prioritization for asthma reassessment once control has been maintained has led to a lack of well-defined procedures for stepping down asthma treatment. However, recent studies provide guidance regarding the risks of stepping down asthma medications. This review uses case-based examples to demonstrate how health care providers may engage patients in discussions regarding guideline recommendations to promote individualized asthma care.",
author = "Hagan, {John B.} and Rank, {Matthew A}",
year = "2015",
month = "4",
day = "1",
doi = "10.1007/s11882-014-0503-z",
language = "English (US)",
volume = "15",
pages = "503",
journal = "Current Allergy and Asthma Reports",
issn = "1529-7322",
publisher = "Current Medicine Group",
number = "8",

}

TY - JOUR

T1 - Assessing the risks and benefits of step-down asthma care

T2 - a case-based approach

AU - Hagan, John B.

AU - Rank, Matthew A

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Guidelines have called for pharmacologic stepped care to improve asthma treatment. Therapeutic options which have been approved provide physicians and their patients alternatives for stepping up asthma treatment to achieve control. However, few studies have been performed to identify and characterize procedures for optimal stepping-down treatment in patients with asthma. The resulting uncertainty as well as a lack of prioritization for asthma reassessment once control has been maintained has led to a lack of well-defined procedures for stepping down asthma treatment. However, recent studies provide guidance regarding the risks of stepping down asthma medications. This review uses case-based examples to demonstrate how health care providers may engage patients in discussions regarding guideline recommendations to promote individualized asthma care.

AB - Guidelines have called for pharmacologic stepped care to improve asthma treatment. Therapeutic options which have been approved provide physicians and their patients alternatives for stepping up asthma treatment to achieve control. However, few studies have been performed to identify and characterize procedures for optimal stepping-down treatment in patients with asthma. The resulting uncertainty as well as a lack of prioritization for asthma reassessment once control has been maintained has led to a lack of well-defined procedures for stepping down asthma treatment. However, recent studies provide guidance regarding the risks of stepping down asthma medications. This review uses case-based examples to demonstrate how health care providers may engage patients in discussions regarding guideline recommendations to promote individualized asthma care.

UR - http://www.scopus.com/inward/record.url?scp=84937218390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937218390&partnerID=8YFLogxK

U2 - 10.1007/s11882-014-0503-z

DO - 10.1007/s11882-014-0503-z

M3 - Article

VL - 15

SP - 503

JO - Current Allergy and Asthma Reports

JF - Current Allergy and Asthma Reports

SN - 1529-7322

IS - 8

ER -